 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 August 1996 | Volume 125 Issue 4 | Pages 265-269
Background: Resistance to activated protein C (APC), which results from various factors, including a mutation in the gene for coagulant factor V, has been associated with increased risk for venous thrombosis. However, its relation to arterial disease is still not well defined.
Objective: To investigate the association of both response to APC and the factor V Leiden mutation with arterial disease.
Design: Population-based case–control study.
Setting: A district of Rotterdam, the Netherlands.
Participants: 115 patients with a history of myocardial infarction; 112 patients with a history of stroke, transient ischemic attack, or both; and 222 age-matched controls without arterial disease chosen from among 7983 persons in the Rotterdam Study cohort. Patients using anticoagulant drugs were excluded.
Measurements: Response to APC was determined in double-centrifuged platelet-poor plasma. Patients were genotyped for the Arg 506 to Gln mutation in the gene for coagulant factor V.
Results: The prevalence of cerebrovascular disease increased gradually and corresponded to a decreasing response to APC (odds ratio per 1-unit decrease of response to APC, 1.43 [95% CI, 1.12 to 1.81], adjusted for age and sex). Adjustment for the factor V mutation did not change the findings. We found no association between response to APC and myocardial infarction or between factor V mutation and cerebrovascular disease or myocardial infarction.
Conclusions: Low response to APC is associated with an increased risk for cerebrovascular disease but not with an increased risk for myocardial infarction, independent of the factor V Leiden mutation. The association between the factor V Leiden mutation and cerebrovascular disease or myocardial infarction remains to be determined.
Author and Article Information
From the Erasmus University Medical School, Rotterdam, the Netherlands; TNO Gaubius Institute for Cardiovascular Research, Leiden, the Netherlands; and the Netherlands Ophthalmic Research Institute, Amsterdam, the Netherlands.
ARTICLE
Reduced Response to Activated Protein C Is Associated with Increased Risk for Cerebrovascular Disease
Acknowledgments: The authors thank the participants in the Rotterdam Study; P.J. Koudstaal, MD, PhD (University Hospital, Rotterdam), for his contribution in establishing the diagnosis of transient ischemic attacks; and all field workers and laboratory technicians in the Ommoord Research Centre and Bas Heijmans from the Gaubius Laboratory for their enthusiasm and skillful contributions to data collection.
Grant Support: The Rotterdam Study is supported in part by the NESTOR program for geriatric research (Ministry of Health and Ministry of Education), the Netherlands Heart Foundation, the Netherlands Organisation for Scientific Research, the Rotterdam Medical Research Foundation, and the Municipality of Rotterdam. Dr. van der Bom is supported by grant 92.398 from the Netherlands Heart Foundation.
Requests for Reprints: Diederick E. Grobbee, MD, PhD, Department of Epidemiology and Biostatistics, Erasmus University Medical School, PO Box 1738, 3000 DR Rotterdam, the Netherlands.
Current Author Addresses: Drs. van der Bom, Bots, Hofman, and Grobbee: Department of Epidemiology and Biostatistics, Erasmus University Medical School, PO Box 1738, 3000 DR Rotterdam, the Netherlands.
This article has been cited by other articles:
|
|
 |
|
  A. Smith, C. Patterson, J. Yarnell, A. Rumley, Y. Ben-Shlomo, and G. Lowe Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke?: The Caerphilly Study Circulation, November 15, 2005; 112(20): 3080 - 3087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Buyru, J. Altinisik, G. Somay, and T. Ulutin Factor V Leiden Mutation in Cerebrovascular Disease Clinical and Applied Thrombosis/Hemostasis, July 1, 2005; 11(3): 339 - 342. [Abstract] [PDF]
|
|
|
|
 |
|
 J. P. Casas, A. D. Hingorani, L. E. Bautista, and P. Sharma Meta-analysis of Genetic Studies in Ischemic Stroke: Thirty-two Genes Involving Approximately 18 000 Cases and 58 000 Controls Arch Neurol, November 1, 2004; 61(11): 1652 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F-J Munoz-Rodriguez, J-C Reverter, J Font, D Tassies, G Espinosa, R Cervera, F Carmona, J Balasch, M Ingelmo, and A Ordinas Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus Lupus, November 1, 2002; 11(11): 730 - 735. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Deguchi, J. A. Fernandez, and J. H. Griffin Neutral Glycosphingolipid-dependent Inactivation of Coagulation Factor Va by Activated Protein C and Protein S J. Biol. Chem., March 8, 2002; 277(11): 8861 - 8865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M L Bots, P C Elwood, Y Nikitin, J T Salonen, A Freire de Concalves, D Inzitari, J Sivenius, V Benetou, J Tuomilehto, P J Koudstaal, et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe J. Epidemiol. Community Health, February 1, 2002; 56(90001): i19 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Boekholdt, N. R. Bijsterveld, A. H.M. Moons, M. Levi, H. R. Buller, and R. J.G. Peters Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction: A Systematic Review Circulation, December 18, 2001; 104(25): 3063 - 3068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington and K. P. Klein Genome and Hormones: Gender Differences in Physiology: Invited Review: Pharmacogenetics of estrogen replacement therapy J Appl Physiol, December 1, 2001; 91(6): 2776 - 2784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tripodi and P. M. Mannucci Laboratory Investigation of Thrombophilia Clin. Chem., September 1, 2001; 47(9): 1597 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Deguchi, J. A. Fernandez, I. Pabinger, J. A. Heit, and J. H. Griffin Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway Blood, April 1, 2001; 97(7): 1907 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Male, L. Mitchell, J. Julian, P. Vegh, P. Joshua, M. Adams, M. David, and M. E. Andrew Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus Blood, February 15, 2001; 97(4): 844 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Bushnell and L. B. Goldstein Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke Stroke, December 1, 2000; 31(12): 3067 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hassan and H. S. Markus Genetics and ischaemic stroke Brain, September 1, 2000; 123(9): 1784 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bonduel, G. Sciuccati, M. Hepner, A. F. Torres, G. Pieroni, and J. P. Frontroth Prethrombotic Disorders in Children With Arterial Ischemic Stroke and Sinovenous Thrombosis Arch Neurol, August 1, 1999; 56(8): 967 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zivelin, S. Gitel, J. H. Griffin, X. Xu, J. A. Fernandez, U. Martinowitz, Y. Cohen, H. Halkin, U. Seligsohn, and A. Inbal Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C Blood, August 1, 1999; 94(3): 895 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Lentz, J. A. Fernandez, J. H. Griffin, D. J. Piegors, R. A. Erger, M. R. Malinow, and D. D. Heistad Impaired Anticoagulant Response to Infusion of Thrombin in Atherosclerotic Monkeys Associated With Acquired Defects in the Protein C System Arterioscler. Thromb. Vasc. Biol., July 1, 1999; 19(7): 1744 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Taube, N. McWilliam, R. Luddington, C. D. Byrne, and T. Baglin Activated Protein C Resistance: Effect of Platelet Activation, Platelet-Derived Microparticles, and Atherogenic Lipoproteins Blood, June 1, 1999; 93(11): 3792 - 3797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Redondo, H. H. Watzke, B. Stucki, I. Sulzer, F. D. Biasiutti, B. R. Binder, M. Furlan, B. Lammle, and W. A. Wuillemin Coagulation Factors II, V, VII, and X, Prothrombin Gene 20210G->A Transition, and Factor V Leiden in Coronary Artery Disease : High Factor V Clotting Activity Is an Independent Risk Factor for Myocardial Infarction Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 1020 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Macko, L. A. Killewich, J. A. Fernandez, D. K. Cox, A. Gruber, and J. H. Griffin Brain-Specific Protein C Activation During Carotid Artery Occlusion in Humans Stroke, March 1, 1999; 30(3): 542 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C.H. de Visser, F. R. Rosendaal, and R. M. Bertina A Reduced Sensitivity for Activated Protein C in the Absence of Factor V Leiden Increases the Risk of Venous Thrombosis Blood, February 15, 1999; 93(4): 1271 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kiechl, A. Muigg, P. Santer, M. Mitterer, G. Egger, M. Oberhollenzer, F. Oberhollenzer, A. Mayr, A. Gasperi, W. Poewe, et al. Poor Response to Activated Protein C as a Prominent Risk Predictor of Advanced Atherosclerosis and Arterial Disease Circulation, February 9, 1999; 99(5): 614 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. deVeber, P. Monagle, A. Chan, D. MacGregor, R. Curtis, S. Lee, P. Vegh, M. Adams, V. Marzinotto, M. Leaker, et al. Prothrombotic Disorders in Infants and Children With Cerebral Thromboembolism Arch Neurol, December 1, 1998; 55(12): 1539 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A LAFFAN Activated protein C resistance and myocardial infarction Heart, October 1, 1998; 80(4): 319 - 321. [Full Text]
|
|
|
|
|
|
J. F. Meschia, J. Biller, T. Witt, A. Greist, and S. N. Rhinehart Is Hormone Replacement a Risk Factor for Ischemic Stroke in Women With Factor V Leiden Mutation? Arch Neurol, August 1, 1998; 55(8): 1137 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Longstreth Jr, F. R. Rosendaal, D. S. Siscovick, H. L. Vos, S. M. Schwartz, B. M. Psaty, T. E. Raghunathan, T. D. Koepsell, and P. H. Reitsma Risk of Stroke in Young Women and Two Prothrombotic Mutations: Factor V Leiden and Prothrombin Gene Variant (G20210A) Stroke, March 1, 1998; 29(3): 577 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S Markus and H. Hambley Neurology and the blood: haematological abnormalities in ischaemic stroke J. Neurol. Neurosurg. Psychiatry, February 1, 1998; 64(2): 150 - 159. [Full Text] [PDF]
|
|
|
|
|
|
B. Kristensen, J. Malm, B. Carlberg, B. Stegmayr, C. Backman, M. Fagerlund, and T. Olsson Epidemiology and Etiology of Ischemic Stroke in Young Adults Aged 18 to 44 Years in Northern Sweden Stroke, September 1, 1997; 28(9): 1702 - 1709. [Abstract] [Full Text]
|
|
|
|
|
|
M. D. Phillips Interrelated Risk Factors for Venous Thromboembolism Circulation, April 1, 1997; 95(7): 1749 - 1751. [Full Text]
|
|
Article
